Published in Ophthalmology on October 01, 2006
Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy | NCT00423059
Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res (2007) 3.67
Vascular endothelial growth factor in eye disease. Prog Retin Eye Res (2008) 2.73
Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol (2008) 2.26
Intravitreal bevacizumab (Avastin) and panretinal photocoagulation in the treatment of high-risk proliferative diabetic retinopathy. J Ocul Pharmacol Ther (2013) 2.20
Short-term topical bevacizumab in the treatment of stable corneal neovascularization. Am J Ophthalmol (2012) 2.14
A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol (2010) 2.04
Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol (2008) 2.03
Microplasmin-induced posterior vitreous detachment affects vitreous oxygen levels. Retina (2007) 1.83
The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. PLoS One (2008) 1.68
Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch Ophthalmol (2009) 1.60
Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol (2008) 1.59
The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc (2012) 1.46
Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol (2008) 1.45
Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol (2007) 1.44
Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up. Graefes Arch Clin Exp Ophthalmol (2009) 1.41
Bevacizumab: off-label use in ophthalmology. Indian J Ophthalmol (2007) 1.35
Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol (2010) 1.34
A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy. Br J Ophthalmol (2012) 1.33
Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol (2014) 1.32
Neovascular glaucoma. Prog Retin Eye Res (2007) 1.31
A review of anti-VEGF agents for proliferative diabetic retinopathy. Eye (Lond) (2014) 1.30
Fellow eye effect of unilateral intravitreal bevacizumab injection in eyes with diabetic macular edema. Eye (Lond) (2014) 1.30
Ocular complications of diabetes mellitus. World J Diabetes (2015) 1.27
Endoplasmic reticulum stress and diabetic retinopathy. Vasc Health Risk Manag (2008) 1.21
On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment - a review. Acta Paediatr (2011) 1.09
Imaging of vascular wall fine structure in the human retina using adaptive optics scanning laser ophthalmoscopy. Invest Ophthalmol Vis Sci (2013) 1.09
Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits. Clin Ophthalmol (2011) 1.08
Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin). Ocul Surf (2012) 1.08
Corneal penetration of topical and subconjunctival bevacizumab. Invest Ophthalmol Vis Sci (2011) 1.07
Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels. J Cell Physiol (2008) 1.06
A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy. Br J Ophthalmol (2011) 1.05
PEDF regulates vascular permeability by a γ-secretase-mediated pathway. PLoS One (2011) 1.05
Ocular pharmacokinetics of bevacizumab in vitrectomized eyes with silicone oil tamponade. Invest Ophthalmol Vis Sci (2012) 1.04
Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability. J Ophthalmol (2011) 1.02
Hypoxia-inducible factor expression in human RPE cells. Br J Ophthalmol (2007) 1.02
Intravitreal injection of bevacizumab and triamcinolone acetonide at the end of vitrectomy for diabetic vitreous hemorrhage: a comparative study. Graefes Arch Clin Exp Ophthalmol (2009) 1.01
Visual outcomes and incidence of recurrent vitreous hemorrhage after vitrectomy in diabetic eyes pretreated with bevacizumab (avastin). Retina (2009) 0.99
MEMS-enabled implantable drug infusion pumps for laboratory animal research, preclinical, and clinical applications. Adv Drug Deliv Rev (2012) 0.99
Role of intravitreal bevacizumab in the management of Eales' disease. Int Ophthalmol (2009) 0.98
Vascular complications and diabetes: current therapies and future challenges. J Ophthalmol (2012) 0.95
What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned? Br J Ophthalmol (2013) 0.93
Microvascular complications and diabetic retinopathy: recent advances and future implications. Future Med Chem (2013) 0.92
Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications. Vasc Health Risk Manag (2007) 0.92
Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture. J Ophthalmol (2011) 0.92
Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmol (2013) 0.91
Subconjunctival bevacizumab as an adjunct to trabeculectomy in eyes with refractory glaucoma: a case series. Korean J Ophthalmol (2010) 0.91
Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis. Ophthalmology (2015) 0.90
Antiangiogenic therapy for ischemic retinopathies. Cold Spring Harb Perspect Med (2012) 0.89
Topical ranibizumab as a treatment of corneal neovascularization. Cornea (2013) 0.89
Serum concentration of vascular endothelial growth factor after bilateral intravitreal injection of bevacizumab. Korean J Ophthalmol (2014) 0.88
Twelve months of follow-up after intravitreal injection of ranibizumab for the treatment of idiopathic parafoveal telangiectasia. Clin Ophthalmol (2013) 0.88
Biocompatible reverse thermal gel sustains the release of intravitreal bevacizumab in vivo. Invest Ophthalmol Vis Sci (2014) 0.87
Intravitreal bevacizumab for the treatment of neovascular glaucoma associated with central retinal artery occlusion. Korean J Ophthalmol (2009) 0.87
Activation of endothelial roundabout receptor 4 reduces the severity of virus-induced keratitis. J Immunol (2011) 0.87
Mini drug pump for ophthalmic use. Trans Am Ophthalmol Soc (2009) 0.86
Changes in choriocapillaris fenestration of rat eyes after intravitreal bevacizumab injection. Graefes Arch Clin Exp Ophthalmol (2009) 0.86
Intra-cameral injection of bevacizumab (Avastin) to treat anterior chamber neovascular membrane in a painful blind eye. Indian J Ophthalmol (2008) 0.86
Cataracts in diabetic patients: a review article. J Ophthalmic Vis Res (2008) 0.86
TWEAK/Fn14 pathway is a novel mediator of retinal neovascularization. Invest Ophthalmol Vis Sci (2014) 0.86
Levels of vascular endothelial growth factor and pigment epithelium-derived factor in eyes before and after intravitreal injection of bevacizumab. Jpn J Ophthalmol (2009) 0.85
Retinal not systemic oxidative and inflammatory stress correlated with VEGF expression in rodent models of insulin resistance and diabetes. Invest Ophthalmol Vis Sci (2012) 0.85
Intravitreal bevacizumab in the treatment of vasoproliferative retinal tumours. Eye (Lond) (2014) 0.85
Vascular endothelial growth factor modulates the function of the retinal pigment epithelium in vivo. Invest Ophthalmol Vis Sci (2014) 0.84
Secondary rhegmatogenous retinal detachment following intravitreal bevacizumab in patients with vitreous hemorrhage or tractional retinal detachment secondary to Eales' disease. Graefes Arch Clin Exp Ophthalmol (2011) 0.84
Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2013) 0.84
Posterior capsule opacification and neovascularization treated with intravitreal bevacizumab and Nd:YAG capsulotomy. Clin Ophthalmol (2008) 0.84
Inhibition of pathological retinal angiogenesis by the integrin αvβ3 antagonist tetraiodothyroacetic acid (tetrac). Exp Eye Res (2011) 0.84
Progression to macula-off tractional retinal detachment after a contralateral intraoperative intravitreal bevacizumab injection for proliferative diabetic retinopathy. Clin Ophthalmol (2015) 0.84
Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases. J Pharmacol Pharmacother (2013) 0.84
Intravitreal bevacizumab for persistent macular edema with proliferative diabetic retinopathy. Int Ophthalmol (2010) 0.84
Intracameral bevacizumab and mitomycin C Trabeculectomy for eyes with neovascular glaucoma: a case series. J Ocul Biol Dis Infor (2009) 0.84
Intravitreal bevacizumab: an analysis of the evidence. Clin Ophthalmol (2007) 0.84
Effects of bevacizumab on the neovascular membrane of proliferative diabetic retinopathy: reduction of endothelial cells and expressions of VEGF and HIF-1α. Mol Vis (2012) 0.83
Intravitreal bevacizumab for proliferative diabetic retinopathy with new dense vitreous hemorrhage after full panretinal photocoagulation. Eye (Lond) (2013) 0.83
Pegaptanib sodium treatment in neovascular age-related macular degeneration: clinical experience in Germany. Clin Ophthalmol (2008) 0.83
Mini drug pump for ophthalmic use. Curr Eye Res (2010) 0.83
Increased vitreous shedding of microparticles in proliferative diabetic retinopathy stimulates endothelial proliferation. Diabetes (2009) 0.83
The Efficacy of Intravitreal Bevacizumab in Vitreous Hemorrhage of Diabetic Subjects. Turk J Ophthalmol (2016) 0.83
Controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration. Open Ophthalmol J (2012) 0.83
Vascular endothelial growth factor in fellow eyes of eyes injected with intravitreal bevacizumab. Graefes Arch Clin Exp Ophthalmol (2008) 0.83
Intravitreal bevacizumab as anti-vascular endothelial growth factor in the management of complications of proliferative diabetic retinopathy. Med Hypothesis Discov Innov Ophthalmol (2013) 0.83
Pharmacotherapies for diabetic retinopathy: present and future. Exp Diabetes Res (2007) 0.82
Retro-mode imaging of fibrovascular membrane in proliferative diabetic retinopathy after intravitreal bevacizumab injection. Clin Ophthalmol (2011) 0.82
Novel pharmacotherapies in diabetic retinopathy: Current status and what's in the horizon? Indian J Ophthalmol (2016) 0.82
Individualised treatment of proliferative diabetic retinopathy: optimal surgical timing improves long-term outcomes. EPMA J (2010) 0.82
Topical application of recombinant calreticulin peptide, vasostatin 48, alleviates laser-induced choroidal neovascularization in rats. Mol Vis (2010) 0.82
Vascular endothelial growth factor expression and inhibition in uveal melanoma cell lines. Ecancermedicalscience (2013) 0.82
Angiofibrotic response to vascular endothelial growth factor inhibition in diabetic retinal detachment: report no. 1. Arch Ophthalmol (2012) 0.82
Bevacizumab as an adjunct to vitreoretinal surgery for diabetic retinopathy in East Africa. Eye (Lond) (2013) 0.82
Current and future approaches in the prevention and treatment of diabetic retinopathy. Clin Ophthalmol (2008) 0.81
Novel Pharmacologic Approaches for the Management of Diabetic Retinopathy. Mol Cell Pharmacol (2009) 0.81
[Intravitreal injection. Monitoring to avoid postoperative complications]. Ophthalmologe (2008) 0.81
Effects of an intravitreal bevacizumab injection combined with panretinal photocoagulation on high-risk proliferative diabetic retinopathy. Korean J Ophthalmol (2009) 0.80
Assessment of patient pain experience during intravitreal 27-gauge bevacizumab and 30-gauge ranibizumab injection. Korean J Ophthalmol (2015) 0.80
Emerging roles for antiangiogenesis factors in management of ocular disease. Clin Ophthalmol (2013) 0.80
Effect of intravitreal bevacizumab on vascular endothelial growth factor expression in patients with proliferative diabetic retinopathy. Yonsei Med J (2011) 0.80
Primary effects of intravitreal bevacizumab in patients with diabetic macular edema. Pak J Med Sci (2013) 0.80
Intravitreal Avastin as an adjunct in patients with proliferative diabetic retinopathy undergoing pars plana vitrectomy. Pak J Med Sci (2013) 0.80
Identification of chemokines and growth factors in proliferative diabetic retinopathy vitreous. Biomed Res Int (2014) 0.79
Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology (2006) 9.01
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med (2015) 7.08
Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology (2006) 5.79
Initial experience using the transconjunctival sutureless vitrectomy system for vitreoretinal surgery. Ophthalmology (2002) 5.10
A new 25-gauge instrument system for transconjunctival sutureless vitrectomy surgery. Ophthalmology (2002) 4.10
A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology (2007) 3.49
Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Invest Ophthalmol Vis Sci (2002) 2.03
Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina (2007) 1.82
Patient selection for macular translocation surgery using the scanning laser ophthalmoscope. Ophthalmology (2002) 1.41
Cloning, expression, and initial characterization of a novel cytokine-like gene family. Genomics (2002) 1.34
Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions. Ophthalmology (2008) 1.20
Endophthalmitis after anti-VEGF injections. Ophthalmology (2009) 1.01
Intravitreal ranibizumab for macular edema secondary to central retinal vein occlusion. Retina (2011) 1.00
Inferior limited macular translocation for subfoveal choroidal neovascularization secondary to age-related macular degeneration: 1-year visual outcome and recurrence report. Am J Ophthalmol (2002) 0.99
Retinal pigment epithelial abnormalities after internal limiting membrane peeling guided by indocyanine green staining. Retina (2004) 0.93
Case of anterior uveitis after intravitreal injection of bevacizumab. Retina (2006) 0.92
A phase ia dose-escalation study of the anti-factor D monoclonal antibody fragment FCFD4514S in patients with geographic atrophy. Retina (2014) 0.89
Leptomeningeal involvement in a patient with splenic lymphoma with villous lymphocytes. Leuk Lymphoma (2002) 0.88
Effect of immunosuppression on pathogenesis of peste des petits ruminants (PPR) virus infection in goats. Microb Pathog (2012) 0.86
A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration. Clin Ophthalmol (2012) 0.85
Semen quality of industrial workers occupationally exposed to chromium. J Occup Health (2005) 0.85
Severe acute vision loss, dyschromatopsia, and changes in the ellipsoid zone on sd-oct associated with intravitreal ocriplasmin injection. Retin Cases Brief Rep (2015) 0.85
Outer retina reflectivity changes on sd-oct after intravitreal ocriplasmin for vitreomacular traction and macular hole. Retina (2015) 0.84
Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2013) 0.84
Angiographic characteristics in patients undergoing macular translocation for subfoveal choroidal neovascularization secondary to age-related macular degeneration. Retina (2003) 0.83
Natural history of minimally classic subfoveal choroidal neovascular lesions in the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation: outcomes potentially relevant to management--TAP report No. 6. Arch Ophthalmol (2004) 0.82
Open globe management. Compr Ophthalmol Update (2007) 0.82
Evaluation of patients with ocular trauma. Ophthalmol Clin North Am (2002) 0.81
Retinal neovascularization associated with a retinal arterial macroaneurysm. Retin Cases Brief Rep (2009) 0.80
Changes in lesion size after submacular surgery for subfoveal choroidal neovascularization in the submacular surgery trials pilot study. Retina (2004) 0.80
Supraspinatus and infraspinatus compartment syndrome following scapular fracture. Int J Shoulder Surg (2013) 0.79
Cystoid macular edema secondary to Paclitaxel (abraxane). Retin Cases Brief Rep (2009) 0.79
Eosinophilic variant of chronic myeloid leukemia with vascular complications. Leuk Lymphoma (2003) 0.78
Unusual presentations of hematologic malignancies: CASE 3. Primary central nervous system B-cell lymphoma of marginal zone B-cell type in a neurosyphilis patient. J Clin Oncol (2004) 0.78
Anterior segment complications following periocular and intraocular injections. Ophthalmol Clin North Am (2004) 0.77
SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB. Retina (2017) 0.77
Frontal air bags and eye injury patterns in automobile crashes. Arch Ophthalmol (2003) 0.75
TREATMENT OF VITREOMACULAR TRACTION WITH INTRAVITREAL PERFLUOROPROPANE (C3F8) INJECTION. Retina (2016) 0.75
Diagnostic and therapeutic challenges. Retina (2007) 0.75
LARGE SILICONE DROPLETS AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN). Retin Cases Brief Rep (2017) 0.75
Diagnostic and therapeutic challenges. Retina (2005) 0.75
A prospective, open-label, dose-escalating study of low molecular weight heparin during repeat vitrectomy for PVR and severe diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol (2005) 0.75
Non-contiguous recurrence or secondary choroidal melanoma following plaque radiotherapy. Clin Experiment Ophthalmol (2007) 0.75
Macular translocation in patients with recurrent subfoveal choroidal neovascularization after laser photocoagulation for nonsubfoveal choroidal neovascularization. Ophthalmology (2004) 0.75
Diagnostic and therapeutic challenges. Retina (2008) 0.75